 PALO ALTO, Calif., June 28, 2021 PRNewswire -- Eiger BioPharmaceuticals, Inc. Nasdaq: EIGR, a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced an oral poster presentation of Phase 2 study results of Avexitide in congenital hyperinsulinism HI at the American Diabetes Association ADA 81st Scientific Session. 